The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis
Open accessAbstract
There is a recently proposed subtype of hepatocellular carcinoma (HCC) that is histologically similar to usual HCC, but characterized by the expression of “stemness”-related markers. A large-scale study on two different cohorts of HCCs was performed to investigate the clinicopathologic features and epithelial-mesenchymal transition (EMT)-related protein expression status of this subtype of HCCs. The expression status of stemness-related (e.g., keratin 19 [K19], cluster of differentiation [CD]133, epithelial cell adhesion molecule [EpCAM], and c-kit) and EMT-related markers (e.g., snail, S100A4, urokinase plasminogen activator receptor [uPAR], ezrin, vimentin, E-cadherin, and matrix metalloproteinase [MMP]2) were examined using tissue microarrays from cohort 1 HCCs (n = 137). K19 protein expression in cohort 2 HCCs (n = 237) was correlated with the clinicopathologic parameters and messenger RNA (mRNA) levels of K19, uPAR, VIL2, Snail, Slug, and Twist. K19, EpCAM, c-kit, and CD133 positivity were observed in 18.2%, 35.0%, 34.3%, and 24.8%, respectively. K19 was most frequently expressed in combination with at least one other stemness-related marker (92.0%). K19-positive HCCs demonstrated more frequent major vessel invasion and increased tumor size, compared to K19-negative HCCs ( P < 0.05). K19 was most significantly associated with EMT-related protein expression (e.g., vimentin, S100A4, uPAR, and ezrin) ( P < 0.05) and a poor prognosis (overall survival: P = 0.018; disease-free survival: P = 0.007) in cohort 1. In cohort 2, HCCs with high K19 mRNA levels demonstrated higher mRNA levels of Snail, uPAR, and MMP2 ( P < 0.05). K19-positive HCCs demonstrated more frequent microvascular invasion, fibrous stroma, and less tumor-capsule formation, compared to K19-negative HCCs ( P < 0.05). K19 expression was a significant independent predictive factor of poor disease-free survival ( P = 0.032). Conclusion: K19 was well correlated with clinicopathologic features of tumor aggressiveness, compared to other stemness-related proteins. K19-positive HCCs showed significantly increased EMT-related protein and mRNA expression, suggesting that they may acquire more invasive characteristics, compared to K19-negative HCCs through the up-regulation of EMT-associated genes. (Hepatology 2011;)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Self-citationModule Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells
Wong, D. J., Liu, H., Ridky, T. W., Cassarino, D., Segal, E., & Chang, H. Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.02.009 · Cited by 720
CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity
Yin, S., Li, J., Hu, C., Chen, X., Yao, M., Yan, M., Jiang, G., Ge, C., Xie, H., Wan, D., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22476 · Cited by 555
Epithelial–mesenchymal transition and the invasive potential of tumors
Gavert, N., & Ben-Ze’ev, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.03.004 · Cited by 352
Liver stem cells and hepatocellular carcinoma†
Mishra, L., Banker, T., Murray, J., Byers, S., Thenappan, A., He, A. R., Shetty, K., Johnson, L., & Reddy, E. P. (2009) · Hepatology · doi:10.1002/hep.22704 · Cited by 333
Yang, X.-R., Xu, Y., Yu, B., Zhou, J., Qiu, S.-J., Shi, G.-M., Zhang, B.-H., Wu, W.-Z., Shi, Y.-H., Wu, B., et al. (2010) · Gut · doi:10.1136/gut.2008.176271 · Cited by 270
Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence
Uenishi, T., Kubo, S., Yamamoto, T., Shuto, T., Ogawa, M., Tanaka, H., Tanaka, S., Kaneda, K., & Hirohashi, K. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01366.x · Cited by 269
uPAR induces epithelial–mesenchymal transition in hypoxic breast cancer cells
Lester, R. D., Jo, M., Montel, V., Takimoto, S., & Gonias, S. L. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200701092 · Cited by 253
Prognostic molecular markers in hepatocellular carcinoma: A systematic review
Mann, C. D., Neal, C. P., Garcea, G., Manson, M. M., Dennison, A. R., & Berry, D. P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.004 · Cited by 218
Progenitor‐derived hepatocellular carcinoma model in the rat†
Andersen, J. B., Loi, R., Perra, A., Factor, V. M., Ledda‐Columbano, G. M., Columbano, A., & Thorgeirsson, S. S. (2009) · Hepatology · doi:10.1002/hep.23488 · Cited by 141
Zheng, Q., Tang, Z., Xue, Q., Shi, D., Song, H.-Y., & Tang, H. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320000146 · Cited by 105
Shan, Y., Huang, Y., Xie, Y.-K., et al. (2010) · Medical Oncology · doi:10.1007/s12032-010-9600-6 · Cited by 94
MicroRNA-492 Is Processed From the Keratin 19 Gene and Up-Regulated in Metastatic Hepatoblastoma σ
von Frowein, J., Pagel, P., Kappler, R., von Schweinitz, D., Roscher, A. A., & Schmid, I. (2010) · Hepatology · doi:10.1002/hep.24125 · Cited by 74
Yoneda, N., Sato, Y., Kitao, A., Ikeda, H., Sawada‐Kitamura, S., Miyakoshi, M., Harada, K., Sasaki, M., Matsui, O., & Nakanuma, Y. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.161 · Cited by 69
Fujii, T., Zen, Y., Harada, K., Niwa, H., Masuda, S., Kaizaki, Y., Watanabe, K., Kawashima, A., & Nakanuma, Y. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.12.010 · Cited by 63
Zhang, Y., Hu, M., Wu, W., Wang, Z., Zhou, K., Zha, X., & Liu, K. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0117-5 · Cited by 45
Na, D. C., Lee, J. E., Yoo, J. E., et al. (2010) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2010.10.003 · Cited by 44
Self-citationPrognostic implications of ezrin expression in human hepatocellular carcinoma
Kang, Y. K., Hong, S. W., Lee, H., & Kim, W. H. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20653 · Cited by 43
Occurrence of c-kit+ Tumor Cells in Hepatitis B Virus-Associated Hepatocellular Carcinoma
Lee, E. S., Han, E. M., Kim, Y., Shin, B. K., Kim, C. H., Kim, H. K., Won, N. H., Yeom, B. W., Kim, I., & Leong, A. S. ‐. (2005) · American Journal of Clinical Pathology · doi:10.1309/lettwn3luf516hr0 · Cited by 29
Self-citation
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Role of epithelial to mesenchymal transition in hepatocellular carcinoma
Giannelli, G., Koudelkova, P., Dituri, F., & Mikulits, W. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.007 · Cited by 615
Molecular and histological correlations in liver cancer
Calderaro, J., Ziol, M., Paradis, V., & Zucman-Rossi, J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.001 · Cited by 590
Metadata
- Authors
- Kim, H., Choi, G. H., Na, D. C., Ahn, E. Y., Kim, G. I., Lee, J. E., Cho, J. Y., Yoo, J. E., Choi, J. S., & Park, Y. N.
- Venue
- Hepatology
- Published
- 2011-11
- Volume
- 54
- Issue
- 5
- Pages
- 1707-1717
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2133503086
- Cited by
- 341
- References
- 20
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.